Back
About the Global Fund
Results Report 2021
-
Programs supported by the Global Fund partnership had saved 44 million lives as of the end of 2020. But over the last year, the impact of the COVID-19 pandemic has been devastating.
- Read the online report
People & Structures
Back
Funding Model
Investments & Results
Explore contributions, investments and results in our fight against AIDS, tuberculosis and malaria around the world.
Back
News
-
11 November 2021
United States to Host Next Global Fund Replenishment Conference -
11 November 2021
Lifeline Support from UNDP and the Global Fund Keeps Afghanistan’s Health Facilities Open -
10 November 2021
Global Fund Board Approves New Strategy Placing People and Communities at Center to Lead Fight Against HIV, TB, Malaria, to Build Systems for Health, Equity and Strengthen Pandemic Preparedness
Updates
Stories
Back
Featured Publication
Documents by type
GF/B22/DP11
Approved by the Board on: 15 December 2010
Expediting transition to fixed-dose combinations of artemisinin-based combination therapies (ACTs)
The Board notes that World Health Organisation (WHO) guidance[1] states that fixed-dose combination formulations (FDCs) of artemisinin-based combination therapies (ACTs) are strongly preferred to co-blistered formulations.
The Board requests the Market Dynamics and Commodities Ad-hoc Committee (MDC) to present recommendations to the Board at the Twenty-Third Board Meeting regarding appropriate transition by recipients of Global Fund financing to the use of FDCs of ACTs.
The Board also requests the MDC to analyze additional measures to accelerate the transition to FDCs of HIV/AIDS and tuberculosis medicines and to present its recommendations to the Board at its Twenty-Fourth Meeting.
[1] WHO Guidelines for the Treatment of Malaria Second Edition (2010). http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.